Switch theme
Sign up to access all valuation multiples
NewAmsterdam Pharma Co NV is a late-stage biopharmaceutical company with a mission to improve patient care in populations with metabolic diseases where currently approved therapies have not been adequate or well tolerated. Its product, obicetrapib, is a next-generation, oral, low-dose CETP inhibitor that is developed to potentially overcome the limitations of current LDL-C lowering treatments.
2019
29
LTM Revenue $30.1M
LTM EBITDA -$184M
$1.6B
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
NewAmsterdam Pharma has a last 12-month revenue of $30.1M and a last 12-month EBITDA of -$184M.
In the most recent fiscal year, NewAmsterdam Pharma achieved revenue of $14.1M and an EBITDA of -$177M.
NewAmsterdam Pharma expects next 12-month revenue of XXX and NTM EBITDA of XXX
See NewAmsterdam Pharma valuation multiples based on analyst estimates| FY 2022 | FY 2023 | FY 2024 | LTM | NTM | |
|---|---|---|---|---|---|
| Revenue | $105M | $14.1M | $33.8M | $30.1M | XXX |
| Gross Profit | n/a | n/a | n/a | XXX | XXX |
| Gross Margin | NaN% | NaN% | NaN% | XXX | XXX |
| EBITDA | -$83.3M | -$177M | -$189M | -$184M | XXX |
| EBITDA Margin | -80% | -1255% | -560% | -610% | XXX |
| Net Profit | -$32.4M | -$83.7M | -$177M | XXX | XXX |
| Net Margin | -31% | -594% | -524% | XXX | XXX |
| Net Debt | n/a | n/a | n/a | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of February 21, 2025, NewAmsterdam Pharma's stock price is $19.
NewAmsterdam Pharma has current market cap of $2.0B, and EV of $1.6B.
See NewAmsterdam Pharma trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $1.6B | $2.0B | XXX | XXX | XXX | XXX | $-2.00 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Sign UpAs of February 21, 2025, NewAmsterdam Pharma has market cap of $2.0B and EV of $1.6B.
NewAmsterdam Pharma's trades at 52.0x LTM EV/Revenue multiple, and -8.5x LTM EBITDA.
Analysts estimate NewAmsterdam Pharma's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See valuation multiples for NewAmsterdam Pharma and 10K+ public comps| FY 2024 | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|
| EV | $1.6B | XXX | XXX | XXX |
| EV/Revenue | 46.4x | XXX | XXX | XXX |
| EV/EBITDA | -8.3x | XXX | XXX | XXX |
| P/E | -10.2x | XXX | XXX | XXX |
| P/E/Growth | n/a | XXX | XXX | XXX |
| EV/FCF | n/a | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Sign UpNewAmsterdam Pharma's NTM/LTM revenue growth is -64%
NewAmsterdam Pharma's revenue per employee for the last fiscal year averaged $0.5M, while opex per employee averaged $6.5M for the same period.
Over next 12 months, NewAmsterdam Pharma's ratio of sales and marketing spend to revenue is estimated to be XXX , while its R&D spend to revenue to be XXX .
Analysts estimate NewAmsterdam Pharma's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See operational valuation multiples for NewAmsterdam Pharma and other 10K+ public comps| FY 2024 | NTM | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|---|
| Revenue Growth | 140% | XXX | XXX | XXX | XXX |
| EBITDA Margin | -560% | XXX | XXX | XXX | XXX |
| EBITDA Growth | 7% | XXX | XXX | XXX | XXX |
| Rule of 40 (SaaS-only) | -624% | XXX | XXX | XXX | XXX |
| Revenue per Employee | $0.5M | XXX | XXX | XXX | XXX |
| Opex per Employee | $6.5M | XXX | XXX | XXX | XXX |
| S&M Expenses to Revenue | 29% | XXX | XXX | XXX | XXX |
| G&A Expenses to Revenue | 183% | XXX | XXX | XXX | XXX |
| R&D Expenses to Revenue | 1131% | XXX | XXX | XXX | XXX |
| Opex to Revenue | 1343% | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Benevolent AI | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
NewAmsterdam Pharma acquired XXX companies to date.
Last acquisition by NewAmsterdam Pharma was XXXXXXXX, XXXXX XXXXX XXXXXX . NewAmsterdam Pharma acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Sign Up| When was NewAmsterdam Pharma founded? | NewAmsterdam Pharma was founded in 2019. |
| Where is NewAmsterdam Pharma headquartered? | NewAmsterdam Pharma is headquartered in United States of America. |
| How many employees does NewAmsterdam Pharma have? | As of today, NewAmsterdam Pharma has 29 employees. |
| Who is the CEO of NewAmsterdam Pharma? | NewAmsterdam Pharma's CEO is Dr. Michael Harvey Davidson, M.D.. |
| Is NewAmsterdam Pharma publicy listed? | Yes, NewAmsterdam Pharma is a public company listed on NAS. |
| What is the stock symbol of NewAmsterdam Pharma? | NewAmsterdam Pharma trades under NAMS ticker. |
| When did NewAmsterdam Pharma go public? | NewAmsterdam Pharma went public in 2022. |
| Who are competitors of NewAmsterdam Pharma? | Similar companies to NewAmsterdam Pharma include e.g. Julphar, Benevolent AI, Galapagos, Pharming. |
| What is the current market cap of NewAmsterdam Pharma? | NewAmsterdam Pharma's current market cap is $2.0B |
| What is the current revenue of NewAmsterdam Pharma? | NewAmsterdam Pharma's last 12-month revenue is $30.1M. |
| What is the current EBITDA of NewAmsterdam Pharma? | NewAmsterdam Pharma's last 12-month EBITDA is -$184M. |
| What is the current EV/Revenue multiple of NewAmsterdam Pharma? | Current revenue multiple of NewAmsterdam Pharma is 52.0x. |
| What is the current EV/EBITDA multiple of NewAmsterdam Pharma? | Current EBITDA multiple of NewAmsterdam Pharma is -8.5x. |
| What is the current revenue growth of NewAmsterdam Pharma? | NewAmsterdam Pharma revenue growth between 2023 and 2024 was 140%. |
| Is NewAmsterdam Pharma profitable? | Yes, NewAmsterdam Pharma is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
